Healthcare - Biotechnology - NASDAQ - US
$ 7.32
1.39 %
$ 1.17 B
Market Cap
-3.01
P/E
INCOME STATEMENT
984 M
REVENUE
-567 M
OPERATING INCOME
-545 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Novavax, Inc.
| Revenue | 984 M |
| Cost Of Revenue | 344 M |
| Gross Profit | 640 M |
| Operating Expenses | 779 M |
| Operating Income | -567 M |
| Other Expenses | -21.4 M |
| Net Income | -545 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | Dec-2007 | Dec-2006 | Dec-2005 | Dec-2004 | Dec-2003 | Dec-2002 | Dec-2001 | Dec-2000 | Dec-1999 | Dec-1998 | Dec-1997 | Dec-1996 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||||||||||||||||||
| Revenue | 983.7 | 1 599.0 | 1 146.3 | 475.6 | 18.7 | 34.3 | 31.2 | 15.4 | 36.2 | 30.7 | 20.9 | 22.1 | 14.7 | 0.3 | 0.3 | 1.1 | 1.5 | 4.7 | 7.4 | 8.3 | 11.8 | 15.0 | 24.1 | 2.5 | 1.2 | 0.7 | 0.5 | 100 K |
| GROSS PROFIT | ||||||||||||||||||||||||||||
| Cost Of Revenue | 343.8 | 902.6 | 12.7 | 747.0 | 113.8 | 0 | 0 | 237.9 | 162.6 | 15.0 | 8.2 | 14.7 | 7.0 | 0 | 0 | 0 | 0.2 | 6.5 | 5.8 | 3.5 | 2.1 | 3.6 | 4.1 | (0.6) | (0.4) | (0.3) | (0.3) | (0.3) |
| Gross Profit | 639.9 | 696.3 | 1 133.6 | (271.4) | (95.2) | 34.3 | 31.2 | (222.6) | (126.4) | 15.7 | 12.7 | 7.4 | 7.7 | 0.3 | 0.3 | 1.1 | 1.3 | (1.8) | 1.6 | 4.8 | 9.7 | 11.4 | 20.0 | 3.1 | 1.6 | 1.0 | 0.8 | 0.4 |
| OPERATING INCOME | ||||||||||||||||||||||||||||
| Operating Expenses | 779.1 | 1 341.0 | 2 832.9 | 892.3 | 148.3 | 208.2 | 202.9 | 284.5 | 193.5 | 99.4 | 65.1 | 37.0 | 29.3 | 38.8 | 37.7 | 35.4 | 31.6 | 22.8 | 10.8 | 29.2 | 25.8 | 33.0 | 29.3 | 15.8 | 6.2 | 6.2 | 5.6 | 5.9 |
| Selling, General and Administrative Expenses | 468.9 | 488.7 | 298.4 | 145.3 | 34.4 | 34.4 | 34.5 | 46.5 | 30.8 | 19.9 | 14.8 | 11.0 | 11.4 | 10.8 | 11.9 | 11.1 | 14.0 | 11.3 | 16.7 | 33.0 | 15.7 | 21.5 | 18.5 | 5.9 | 2.4 | 2.5 | 2.4 | 1.9 |
| Research and Development Expenses | 737.5 | 1 235.3 | 2 534.5 | 747.0 | 113.8 | 173.8 | 168.4 | 237.9 | 162.6 | 79.4 | 50.3 | 26.1 | 17.9 | 28.0 | 25.8 | 24.3 | 17.6 | 11.5 | 5.1 | 7.4 | 10.1 | 11.5 | 10.8 | 9.4 | 3.4 | 3.4 | 2.9 | 3.7 |
| Operating Income | (566.5) | (644.7) | (1 686.6) | (416.7) | (120.6) | (173.9) | (171.7) | (269.1) | (157.2) | (83.7) | (52.4) | (29.7) | (21.6) | (38.5) | (37.4) | (34.4) | (30.3) | (24.6) | (9.2) | (24.5) | (16.1) | (21.6) | (9.3) | (12.7) | (4.6) | (5.2) | (4.8) | (5.5) |
| PRE-TAX INCOME | ||||||||||||||||||||||||||||
| Interest Income Expense | 14.4 | 19.9 | 21.1 | 15.1 | 12.2 | 12.2 | 14.1 | 13.0 | 0.2 | 0.2 | 0.2 | 32 K | 9 K | 9 K | 0.5 | 1.7 | 1.6 | 1.5 | 2.0 | 1.5 | 1.2 | 1.1 | 0.5 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 23.5 | (8.9) | (28.0) | (1.5) | (12.1) | (10.8) | (12.1) | (10.9) | 0.3 | 0.7 | 0.5 | 1.2 | 2.6 | 2.3 | (1.0) | (1.7) | 1.7 | 1.5 | (2.0) | (1.5) | (1.2) | (1.1) | (0.5) | 0 | 0 | 0.3 | 0.2 | 100 K |
| Pre-Tax Income | (543.0) | (653.6) | (1 714.5) | (418.3) | (132.7) | (184.7) | (183.8) | (280.0) | (156.9) | (82.9) | (52.0) | (28.5) | (19.0) | (36.2) | (38.4) | (36.0) | (34.8) | (23.1) | (11.2) | (25.9) | (17.3) | (22.7) | (9.7) | 0 | 0 | (4.9) | (4.6) | (5.4) |
| NET INCOME | ||||||||||||||||||||||||||||
| Tax Provision | 2.0 | 4.3 | 29.2 | 9.2 | (2.6) | 1.4 | 2.3 | 2.3 | (6.4) | (5.2) | 25 K | 77 K | 0.4 | (0.5) | (0.2) | 1.7 | (0.7) | 0 | 2.0 | 1.5 | 0 | 0 | 0 | (0.6) | 100 K | (0.4) | (0.3) | 100 K |
| Net Income | (545.1) | (657.9) | (1 743.8) | (427.5) | (130.1) | (184.7) | (183.8) | (280.0) | (156.9) | (82.9) | (52.0) | (28.5) | (19.4) | (35.7) | (38.4) | (36.0) | (34.8) | (23.1) | (11.2) | (25.9) | (17.3) | (22.7) | (9.7) | (12.2) | (4.5) | (4.8) | (4.5) | (5.5) |
| EPS | 5.41 | 8.42 | 23.4 | 7.43 | 5.4 | 9.99 | 12.6 | 20.7 | 12 | 7.35 | 6.13 | 4.33 | 3.41 | 6.82 | 8.97 | 10.6 | 11.4 | 7.86 | 5.23 | 14 | 11.6 | 18.6 | 8.6 | 12.8 | 6.2 | 7.72 | 7.71 | 10.9 |